European Neuropsychopharmacology (v.19, #S2)
P.2.10 Cost-effectiveness in the pharmacoeconomics of depression treatment by L. Kavaliauskiene; V. Adomaitiene; R. Peciura (S150).
P.2.09 Serotonin transporter gene promoter polymorphism and family relations: effect on symptoms of depression in adolescents by T. Kurrikoff; L. Merenäkk; N. Nordquist; L. Oreland; J. Harro (S149-S150).
P.2.08 Long term follow up of adolescent depression: history of drug prescriptions by A. Päären; A.L. von Knorring; L. von Knorring (S148-S149).
P.3.01 Aripiprazole reduces risperidone-induced hyperprolactinemia: two case reports by A. Capasso; W. Milano; L. Milano; C. Siano; C. Petrella (S151).
P.3.02 Osteopenia by risperidone-induced hyperprolactinemia: a case report by A. Capasso; L. Milano; C. Petrella; C. Siano; W. Milano (S151-S152).
P.3.05 Need-adapted treatment of first episode psychotic patients: 2-year follow-up by H. Küünarpuu; K. Küünarpuu (S154).
P.3.04 Cognitive functions and level of stress in schizophrenia-like psychoses before treatment and during quetiapine therapy by A. Wysokinski; M. Talarowska; A. Orzechowska; W. Gruszczynski; K. Zboralski (S153-S154).
P.3.03 Population study of remission rate in an outpatient psychiatric service in Moscow by A. Potapov; U. Dedurina; E. Tsukarzi; S. Mosolov (S152-S153).
P.2.07 Comparison of the effectiveness of trazodone and venlafaxine therapy in patients with diagnosed depressive disorders by K. Zboralski; A. Florkowski; M. Talarowska; A. Wysokinski; P. Galecki (S147-S148).
P.2.06 Effects of serotoninergic agents on depressive-like behaviour and anxiety in old thyroidectomized rats by O. Masalova (S147).
P.1.16 Characterisation of ligand binding to melanocortin 4 receptors by fluorescence polarisation by S. Veiksina; S. Kopanchuk; A. Rinken (S142-S143).
P.1.15 Chronic citalopram treatment counteracts kainic acid induced aberrations in adult mouse hippocampus by M. Helmdorf; D. Sastin; K. Jaako; A. Zharkovsky (S142).
P.1.14 Antiaggressive and sedative effect of alpha2-adrenoceptor agonist naphthylmedetomidine in rabbits and monkeys by M. Votava; L. Hess; J. Schreiberová; J. Málek (S141-S142).
P.2.01 Duloxetine in the treatment of bulimia nervosa: a case report by A. Capasso; C. Siano; G. Nolfe; C. Petrella; L. Milano; W. Milano (S143-S144).
P.2.02 Citalopram and venlafaxine in the treatment of depressive disorder in elderly patients by P. Galecki; A. Florkowski; A.P. Jurczyk; K. Bobinska; T. Pietras; K. Zboralski (S144-S145).
P.2.05 Effects of the NMDA antagonist MK-801 on the behavioural manifestations of antidepressants in rats by K. Pruus; L. Allikmets (S146).
P.2.04 Trends in treating depression of inpatients with ischaemic heart disease in university hospital by V. Adomaitiene; R. Babarskiene; E. Sepetauskiene; S. Sajauskiene; G. Jasaite (S145-S146).
P.3.06 Composite tardive dystonia associated with antipsychotic drugs for treatment of bipolar affective disorder: a case study by V. Adomaitiene; D. Rastenyte; A. Sveikata; G. Gumbrevicius; K. Lauckaite (S154-S155).
P.3.07 Quality of life of family members of patients with first episode psychosis and family-centered treatment by L. Reinson (S155-S156).
P.7.03 Brain-derived neurotrophic factor gene val66met polymorphism, smoking and suicide-related thoughts in adolescents by K. Hiio; J. Parik; L. Merenäkk; J. Harro (S165).
P.7.02 Hypoxic impact in the period of early organogenesis disturbs corticosterone levels in the adrenal glands and blood of pregnant rats by T.Y. Dunaeva; L.K. Trofimova; A.A. Baizhumanov; E.N. Goncharenko; A.V. Graf; Y.V. Krushinskaya; E.E. Chirazova; M.V. Maslova (S164).
P.7.01 Hyperactive and inattentive symptoms, hostile family environment, and ADRA2A C-1291G polymorphism in healthy adolescents by E. Kiive; T. Kurrikoff; J. Mäestu; J. Harro (S163-S164).
P.8.01 Mental retardation – psychopathology, diagnosing and treatment – forty years after Webster's theory by K. Bobinska; P. Galecki; J. Smigielski; A. Florkowski; J. Szemraj (S165-S166).
P.8.02 The hydrolysis of 7-bromo-3-hydroxy-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepine-2-one esters by pig liver microsomes by I.I. Romanovskaya; E.A. Shesterenko; O.V. Sevastyanov; E.A. Semenishina; V.I. Pavlovsky; S.A. Andronati (S166-S167).
Keyword Index (S171).
Author Index (S169-S170).
P.8.03 Cognitive dysfunctions in a group of patients with fibromyalgia and its consequences for treatment by W. Samborski; E. Mojs (S167-S168).
P.6.02 Substance use and serotonin transporter gene L/S polymorphism in children and adolescents by L. Merenäkk; J. Mäestu; T. Kurrikoff; N. Nordquist; L. Oreland; J. Harro (S162-S163).
P.6.01 Incentive role of amygdaloid CRF receptors in the reinforcing effects of psychoactive drugs in rats: a new concept by P. Shabanov; A.A. Lebedev (S161-S162).
P.4.02 Influence of drugs with anxiolytic properties on serotonergic receptors in the rat brain by M. Kowalczyk; S. Rump (S157-S158).
P.4.01 Effects of group II metabotropic glutamate receptor antagonist, MGS0039 in rodent tests of anxiety-like behaviour by K. Stachowicz; H. Domin; A. Pilc (S156-S157).
P.3.08 Possible neurophysiological endophenotypes of schizophrenia at the different stages of illness progression by I. Lebedeva; V.G. Kaleda; L.I. Abramova; A.N. Barkhatova; S.A. Golubev (S156).
P.4.03 Influence of antenatal intermittent normobaric hypoxia in the period of early organogenesis on the behaviour of rats by L. Trofimova; A.V. Graf; T.Y. Dunaeva; M.V. Maslova; E.E. Hirazova; A.S. Maklakova; N.A. Sokolova (S158-S159).
P.4.04 Interaction between CRF and noradrenergic system in the rat frontal cortex by B. Zieba; H. Domin; K. Stachowicz; M. Smialowska (S159-S160).
P.4.06 Trazodone – efficacious way to treat adjustment disorders by P. Galecki; K. Bobinska; K. Zboralski; D. Berent; A. Florkowski (S160-S161).
P.4.05 Trends in use of diazepam in university hospital by V. Adomaitiene; B. Varanaviciene; O. Anciulyte (S160).
P.1.13 Identification of clusters of co-regulated genes that may underlie the phenotypes of high and low exploring rats by A. Alttoa; T.A. Hinsley; K. Kõiv; J. Harro (S140-S141).
P.1.12 Response to chronic social stress in the rat depends on persistent differences in sucrose consumption by M. Kanarik; K. Kõiv; D. Matrov; J. Harro (S139-S140).
S.2.02 The brain prepared to become anxious: predisposing neurobiology in animals and humans by J. Harro; A. Alttoa; L. Herm; E. Kiive; T. Kurrikoff; J. Mäestu; T. Mällo; L. Merenäkk; N. Nordquist; L. Oreland (S113-S115).
S.2.01 Can PTSD be prevented? Strategic interventions in the ‘golden hours’ by J. Zohar (S111-S113).
S.1.05 Depression and general medical condition by R. Bunevicius (S111).
S.2.03 The role of 5-HT1A receptors in emotional memory: implications for anxiety and depression by S.O. Ögren; T.M. Eriksson; J. Kehr; P. Svenningsson; O. Stiedl (S115-S116).
S.2.04 Are antidepressants really endowed with anxiolytic properties in relevant animal models? by M. Hamon; R. Mongeau; C. Martin; M.H. Thiebot; L. Lanfumey (S116-S117).
S.3.02 Molecular genetics of ADHD by K.P. Lesch (S120-S121).
S.3.01 Gene–environment interactions in schizophrenia by O. Mors; A. Borglum; D. Hougaard; P.B. Mortensen (S119-S120).
S.2.05 Wolframin (WFS1) deficient mice display increased anxiety and reduced adaptation in a novel environment by E. Vasar; S. Kõks; H. Luuk; M. Plaas; S. Sütt; S. Raud; K. Kurrikoff; U. Abramov; J. Innos (S117-S119).
S.1.04 Prediction of suicide in mood disorders by Z. Rihmer (S110-S111).
S.1.03 Male depression and suicide by W. Rutz (S109).
KL.02 The European First Episode Schizophrenia Trial: are all antipsychotics created equal? by R. Kahn (S103-S104).
KL.01 Bipolar disorders by G.M. Goodwin; R. Chandler; R.D. Rogers (S103).
ME1 Treatment of schizophrenia by C. Arango (S105).
ME2 Use of dual action antidepressants by S. Kasper (S105-S106).
S.1.02 Antidepressant pharmacotherapy – 2009 and beyond by D. Nutt (S108-S109).
S.1.01 New molecules for mood disorders; the NewMood EU project by J.F.W. Deakin (S107-S108).
S.3.03 Pharmacogenetic studies in depression by E. Maron (S121-S122).
S.3.05 Developmental programming of anxiety in mice by C. Gross; L. Lo Iacono; T. Tsetsenis; T. Ferreira; A. Gruart; J.M. Delgado-Garcia; A. Fernandez-Guizan (S122-S123).
P.1.07 Prodrugs of 3-hydroxy-7-brom-5-phenyl- 1,4-benzdiazepin-2-on for oral delivery by I. Kravchenko; I. Radaeva (S135-S136).
P.1.06 Ketanzerine improves cognitive performance in ovariectomized rats with scopolamine-induced amnesia by J. Fedotova; N. Platonova (S135).
P.1.05 The influence of the new analogue of AVP(6–9) – Ac-D-SPRG on the behaviour in white rats by A. Belyakova; O.G. Voskresenskaya; A.A. Kamensky; V.P. Golubovich (S134).
P.1.08 Mice deficient in ST8SiaII demonstrate working memory impairment: a core feature of schizophrenia-like phenotype by K. Malinovskaja; A. Aonurm-Helm; A. Kalda; A. Zharkovsky (S136-S137).
P.1.09 Psychoemotional state and cancerous growth metastases: possible roles of vasopressin by N. Popova; V. Nikolin; S. Ilnitskaya; M. Belyaev; A. Amikishieva; A. Kolobov; V. Kaledin (S137).
P.1.11 Neurochemical effects of prenatal exposure of selective M- and N-cholinoblockers in early ontogeny by A.A. Bairamov; A.O. Poletaeva; G.Y. Yukina; S.K. Meshcherov; S.N. Proshin; N.S. Mamina; N.S. Sapronov (S138-S139).
P.1.10 Acute hypoxia of early organogenesis: influence on stress-realising system of descendants by A. Graf; T.U. Dunaeva; L.K. Trofimova; N.A. Sokolova; Y.A.V. Krushinskaya; A.A. Bayzhymanov; E.N. Goncharenko (S138).
P.1.04 Depression-like behaviour and reduced levels of the serotonin reuptake transporter in the brain regions of NCAM deficient mice by A. Aonurm-Helm; A. Zharkovsky (S133-S134).
P.1.03 Effects of chronic citalopram treatment on the kainic acid induced neurogenesis in adult mouse hippocampus by K. Jaako; T. Zharkovskaja; A. Zharkovsky (S132-S133).
S.4.03 Neural cell adhesion molecule and depression-like phenotype in mice by A. Zharkovsky; A. Aonurm-Helm; T. Zharkovsky; V. Beresin; E. Bock (S126-S127).
S.4.02 Time course in evolution of brain amyloid and its relation to cognitive impairment in Alzheimer's disease by A. Nordberg; A. Forsberg; A. Kadir; O. Almkvist; H. Engler; B. Långström (S125-S126).
S.4.01 Neuroplasticity and neuronal cell adhesion molecules by E. Bock; P.S. Walmod; T. Secher; V. Berezin (S123-S125).
S.4.04 Pharmacological induction of neuronal plasticity in the visual cortex by E. Castrén (S127-S128).
S.4.05 Novel neurotrophic factors for the treatment of neurodegenerative diseases by M. Saarma (S128-S129).
P.1.02 Effect of repeated haloperidol administration on maternal behaviour of albino rats by Y.V. Dobryakova; V.A. Dubynin; A.A. Kamenskii (S132).
P.1.01 The kinurenine pathway gene polymorphisms of the tryptophan metabolism do not play a role in Alzheimer's disease by A. Juhasz; A. Feher; A. Rimanoczy; M. Galfi; J. Kalman; Z. Janka (S131).
Editorial Board (i-ii).